NuPathe Inc. (NASDAQ: PATH) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food & Drug Administration (FDA) regarding the New Drug Application (NDA) for its migraine patch (Zelrix). PATH shares plunged to $2.06 at pre-market trading hours.
PATH traded over 5.7M shares compared to 204K 10day average volume.
227 Washington Street
Conshohocken, PA 19428
NuPathe Inc. a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders.